{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:31:22Z","timestamp":1786444282886,"version":"build-2736575974"},"reference-count":36,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15754","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T10:43:31Z","timestamp":1783507411000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Survival benefits of non\u2011surgical triple therapy in hepatocellular carcinoma with inferior vena cava\/right atrial tumor thrombus: A retrospective analysis from a multidisciplinary team"],"prefix":"10.3892","volume":"32","author":[{"given":"Peng","family":"Tang","sequence":"first","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zeng","sequence":"additional","affiliation":[{"name":"Division of Liver Surgery, Department of General Surgery and Laboratory of Liver Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"key20260811124507_b1-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","article-title":"Hepatocellular carcinoma: Updates on epidemiology, surveillance, diagnosis and treatment","volume":"31","author":"Hwang","year":"2005","journal-title":"Clin Mol Hepatol"},{"key":"key20260811124507_b2-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"key20260811124507_b3-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"key20260811124507_b4-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1186\/s12885-019-5870-3","article-title":"Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava\/right atrium tumor thrombus: A multi-center analysis","volume":"19","author":"Lou","year":"2019","journal-title":"BMC Cancer"},{"key":"key20260811124507_b5-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"key20260811124507_b6-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"key20260811124507_b7-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260811124507_b8-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/hep.29225","article-title":"Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey","volume":"66","author":"Kokudo","year":"2017","journal-title":"Hepatology"},{"key":"key20260811124507_b9-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1097\/SLA.0000000000005789","article-title":"Liver resection for hepatocellular carcinoma with tumor thrombus in the inferior vena cava or right atrium: A large-scale multicenter survey conducted in Japan","volume":"278","author":"Ichida","year":"2023","journal-title":"Ann Surg"},{"key":"key20260811124507_b10-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.3390\/ijms24032685","article-title":"FDA-approved monoclonal antibodies for unresectable hepatocellular carcinoma: What do we know so far?","volume":"24","author":"Psilopatis","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260811124507_b11-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"516","DOI":"10.3350\/cmh.2023.0051","article-title":"Systemic therapy in advanced hepatocellular carcinoma","volume":"29","author":"Ahn","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"key20260811124507_b12-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41575-020-00395-0","article-title":"Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma","volume":"18","author":"Llovet","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20260811124507_b13-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"key20260811124507_b14-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.cgh.2014.03.038","article-title":"Building the multidisciplinary team for management of patients with hepatocellular carcinoma","volume":"13","author":"Naugler","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"key20260811124507_b15-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"717","DOI":"10.21037\/hbsn.2019.10.07","article-title":"A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus","volume":"9","author":"Chen","year":"2020","journal-title":"Hepatobiliary Surg Nutr"},{"key":"key20260811124507_b16-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"key20260811124507_b17-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3892\/ol.2020.11962","article-title":"Diagnosis, treatment and prognosis of hepatocellular carcinoma with inferior vena cava\/right atrium tumor thrombus","volume":"20","author":"Xia","year":"2020","journal-title":"Oncol Lett"},{"key":"key20260811124507_b18-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1245\/s10434-012-2646-2","article-title":"Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava\/right atrium tumor thrombus: Results of a retrospective cohort study","volume":"20","author":"Wang","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"key20260811124507_b19-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/1477-7819-11-259","article-title":"Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium","volume":"11","author":"Wakayama","year":"2013","journal-title":"World J Surg Oncol"},{"key":"key20260811124507_b20-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"key20260811124507_b21-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","article-title":"Precision treatment in advanced hepatocellular carcinoma","volume":"42","author":"Yang","year":"2024","journal-title":"Cancer Cell"},{"key":"key20260811124507_b22-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: Current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J Hematol Oncol"},{"key":"key20260811124507_b23-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"key20260811124507_b24-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"7746","DOI":"10.4049\/jimmunol.175.11.7746","article-title":"Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade","volume":"175","author":"Maker","year":"2005","journal-title":"J Immunol"},{"key":"key20260811124507_b25-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1200\/JCO.23.01462","article-title":"Patient-reported outcomes from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"42","author":"Sangro","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260811124507_b26-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"key20260811124507_b27-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"key20260811124507_b28-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s12072-023-10502-3","article-title":"Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma","volume":"17","author":"Xin","year":"2023","journal-title":"Hepatol Int"},{"key":"key20260811124507_b29-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","article-title":"Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence","volume":"72","author":"Raoul","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"key20260811124507_b30-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","article-title":"Stereotactic body radiotherapy vs sorafenib alone in hepatocellular carcinoma: The NRG oncology\/RTOG 1112 phase 3 randomized clinical trial","volume":"11","author":"Dawson","year":"2025","journal-title":"JAMA Oncol"},{"key":"key20260811124507_b31-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20260811124507_b32-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): A randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"key20260811124507_b33-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"key20260811124507_b34-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"848387","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: A retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunol"},{"key":"key20260811124507_b35-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5582\/bst.2021.01173","article-title":"The multidisciplinary management of hepatocellular carcinoma with portal vein tumor thrombus","volume":"15","author":"Qiu","year":"2021","journal-title":"Biosci Trends"},{"key":"key20260811124507_b36-ol-32-3-15754","doi-asserted-by":"publisher","first-page":"m3544","DOI":"10.1136\/bmj.m3544","article-title":"New advances in the diagnosis and management of hepatocellular carcinoma","volume":"371","author":"Yang","year":"2020","journal-title":"BMJ"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:45:11Z","timestamp":1786441511000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":36,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15754","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]}}}